

## Supplementary Online Content

Sheikh S, Ho ML, Eisner M, et al. Elexacaftor-tezacaftor-ivacaftor therapy for chronic sinus disease in cystic fibrosis. *JAMA Otolaryngol Head Neck Surg*. Published online September 7, 2023. doi:10.1001/jamaoto.2023.2701

**eTable 1.** Agreement Percentage and  $\kappa$  Values Among 3 Sinus CT Reviewers

**eTable 2.** Comparison of Clinical Outcomes 1 Year vs 1 Year of Receiving ETI and Number of Participants Receiving Therapies at the Start Compared With 1 Year of Receiving ETI

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Agreement Percentage and  $\kappa$  Values Among 3 Sinus CT Reviewers

<b>Parameter</b>	<b>Subjects</b>	<b>% Agreement</b>	<b>Kappa<sup>1</sup></b>	<b>95% CI<sup>2</sup></b>
SL start right maxillary opacification	64	78.1	0.77	0.67-0.87
SL start right nasal cavity obstruction	64	84.4	0.78	0.68-0.88
SL start right displacement of lateral nasal wall	64	90.6	0.22	0.08-0.36
SL start right uncinate process absence	64	92.2	0.56	0.41-0.7
SL start right mucocele	64	90.6	0.81	0.67-0.95
SL start left maxillary opacification	64	82.8	0.82	0.72-0.92
SL start left nasal cavity obstruction	64	68.8	0.62	0.52-0.72
SL start left displacement of lateral nasal wall	64	78.1	0.14	0-0.28
SL start left uncinate process absence	64	93.8	0.58	0.44-0.72
SL start left mucocele	64	82.8	0.68	0.53-0.82
SL 1-year right maxillary opacification	64	87.5	0.66	0.55-0.77
SL 1-year right nasal cavity obstruction	64	64.1	0.22	0.08-0.36
SL 1-year right displacement of lateral nasal wall	64	90.6	0.11	-0.03-0.25
SL 1-year right uncinate process absence	64	96.9	0.74	0.6-0.88
SL 1-year right mucocele	64	95.3	0.73	0.59-0.87
SL 1-year left maxillary opacification	64	71.9	0.49	0.38-0.6
SL 1-year left nasal cavity obstruction	64	75.0	0.02	-0.11-0.16
SL 1-year left displacement of lateral nasal wall	64	90.6	0.22	0.08-0.36
SL 1-year left uncinate process absence	64	93.8	0.69	0.55-0.83
SL 1-year left mucocele	64	93.8	0.73	0.59-0.87
LM start right frontal sinus	64	78.1	0.73	0.63-0.83
LM start right anterior ethmoid	64	76.6	0.66	0.54-0.79
LM start right posterior ethmoid	64	81.2	0.65	0.54-0.76
LM start right maxillary sinus	64	81.2	0.63	0.5-0.76
LM start right sphenoid sinus	64	76.6	0.67	0.56-0.78
LM start right ostiomeatal occlusion	64	87.5	0.55	0.41-0.69
LM start left frontal sinus	64	68.8	0.60	0.5-0.71
LM start left anterior ethmoid	64	65.6	0.49	0.37-0.61
LM start left posterior ethmoid	64	75.0	0.48	0.37-0.59
LM start left maxillary sinus	64	78.1	0.59	0.46-0.72
LM start left sphenoid sinus	64	67.2	0.59	0.48-0.7
LM start left ostiomeatal occlusion	64	82.8	0.60	0.46-0.74
LM 1-year right frontal sinus	64	71.9	0.64	0.53-0.74
LM 1-year right anterior ethmoid	64	54.7	0.25	0.11-0.38
LM 1-year right posterior ethmoid	64	39.1	0.15	0.01-0.29

**eTable 1.** Agreement Percentage and  $\kappa$  Values Among 3 Sinus CT Reviewers

<b>Parameter</b>	<b>Subjects</b>	<b>% Agreement</b>	<b>Kappa<sup>1</sup></b>	<b>95% CI<sup>2</sup></b>
LM 1-year right maxillary sinus	64	78.1	0.43	0.29-0.57
LM 1-year right sphenoid sinus	64	54.7	0.43	0.3-0.56
LM 1-year left frontal sinus	64	75.0	0.64	0.53-0.75
LM 1-year left anterior ethmoid	64	62.5	0.41	0.29-0.53
LM 1-year left posterior ethmoid	64	43.8	0.23	0.09-0.36
LM 1-year left maxillary sinus	64	78.1	0.40	0.26-0.54
LM 1-year left sphenoid sinus	64	51.6	0.32	0.19-0.45

<sup>1</sup>Kappa interpretation: slight agreement, 0.20 or less; fair agreement, 0.21-0.40; moderate agreement, 0.41-0.60; good agreement, 0.61-0.80; very good agreement, 0.81-1.00.

<sup>2</sup>CI = Confidence Interval

LM: Lund-Mackay, SL-Sheikh-Lind

**eTable 2.** Comparison of Clinical Outcomes 1 Year vs 1 Year of Receiving ETI and Number of Participants Receiving Therapies at the Start Compared With 1 Year of Receiving ETI

<b>Characteristic</b>	<b>1-year before ETI, N = 64<sup>1</sup></b>	<b>1-year after ETI, N = 64<sup>1</sup></b>	<b>Effect size<sup>2</sup></b>	<b>95% CI<sup>2,3</sup></b>
CF exacerbations	3.50 (1.00, 6.00)	0 (0, 1.00)	1.4	1.0, 1.8
Hospital admissions	1.00 (0, 1.25)	0 (0, 0)	0.80	0.44, 1.2
I/V antibiotics	1.00 (0, 1.25)	0 (0, 0)	1.0	0.65, 1.4
Oral/neb antibiotics	2.00 (1.00, 4.25)	0 (0, 1.00)	1.3	0.94, 1.7
Chest therapy (VEST)	63 (98%)	52 (81%)	0.50	0.24, 0.50
Pulmozyme	59 (92%)	26 (41%)	0.50	0.40, 0.50
Hypersal therapy	42 (66%)	18 (28%)	0.50	0.36, 0.50
Intranasal steroids	41 (64%)	35 (55%)	0.50	0.11, 0.50
Nasal saline irrigations	33 (52%)	25 (39%)	0.50	0.18, 0.50
Nebulized antibiotics for sinopulmonary disease	18 (28%)	8 (12%)	0.50	0.22, 0.50
Culture method			0.47	0.35, 0.49
Sputum	46 (72%)	15 (24%)		
Throat swab	18 (28%)	48 (76%)		

<sup>1</sup>Median (IQR); n (%)

<sup>2</sup>Cohen's d; Cohen's g

<sup>3</sup>CI = Confidence Interval